DJSI World recognizes the top 10 percent of most sustainable
companies by industry; Regeneron ranked among top three
biotechnology companies1
TARRYTOWN, N.Y., Dec. 12,
2022 /PRNewswire/ -- Regeneron Pharmaceuticals,
Inc. (NASDAQ: REGN) today announced that the company
has been included on the Dow Jones Sustainability World Index (DJSI
World) for the fourth consecutive year and on the Dow Jones
Sustainability North America Index (DJSI North America) for the
third year. These indices recognize Regeneron's enduring
leadership in supporting its patients, colleagues, communities and
planet.
DJSI World is a pioneering global index comprised of the top 10
percent of the of most sustainable companies in each industry based
on performance across environmental, social and governance (ESG)
criteria using a best-in-class approach. Regeneron ranked among the
top three biotechnology companies globally.1 Out of the
2,500 largest companies eligible for inclusion on this year's DJSI
World Index, Regeneron is one of only six companies in the
biotechnology sector selected.
"We are proud that Regeneron's long-standing commitment to
corporate responsibility has once again been highlighted through
inclusion in the Dow Jones Sustainability World Index,"
said Leonard S. Schleifer, M.D., Ph.D., President and
Chief Executive Officer of Regeneron. "From the beginning,
corporate responsibility has been integrated into every part of our
business. Through our distinctive science-led approach, we are
advancing our 2025 responsibility goals to create a more
sustainable, healthier world and build business resiliency."
Regeneron's 2025 responsibility goals focus on the environmental
and social issues that matter most to society and its business, and
are part of the company's long-standing commitment
to corporate responsibility. Regeneron provides an overview of
responsibility efforts and progress to date in its
annual Responsibility Report. In addition to DJSI World
and North America, Regeneron has
received a number of other recognitions, including inclusion on the
Civic 50, a list of the 50 most community-minded companies
in the United States and the
FTSE4Good Index, a list of companies with leading ESG
practices.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents, develops and commercializes
life-transforming medicines for people with serious diseases.
Founded and led for nearly 35 years by physician-scientists, our
unique ability to repeatedly and consistently translate science
into medicine has led to nine FDA-approved treatments and numerous
product candidates in development, almost all of which were
homegrown in our laboratories. Our medicines and pipeline are
designed to help patients with eye diseases, allergic and
inflammatory diseases, cancer, cardiovascular and metabolic
diseases, hematologic conditions, infectious diseases and rare
diseases.
Regeneron believes that operating as a good corporate citizen is
crucial to delivering on our mission. We approach corporate
responsibility with three goals in mind: to improve the lives of
people with serious diseases, to foster a culture of integrity and
excellence and to build sustainable communities. Regeneron is proud
to be included on the Dow Jones Sustainability World Index and the
Civic 50 list of the most "community-minded" companies in the U.S.
Throughout the year, Regeneron empowers and supports employees to
give back through our volunteering, pro bono and matching gift
programs. Our most significant philanthropic commitments are in the
area of early science education, including the Regeneron Science
Talent Search and the Regeneron International Science and
Engineering Fair (ISEF).
For more information, please visit www.Regeneron.com or
follow @Regeneron on Twitter.
1Based on scores available as of December 9, 2022
Regeneron
Contacts:
Media
Relations
Tina Parisi
Tuttle
Tina.Parisituttle@regeneron.com
|
Investor
Relations
Vesna
Tosic
Vesna.Tosic@regeneron.com
|
View original
content:https://www.prnewswire.com/news-releases/regeneron-named-on-dow-jones-sustainability-world-index-for-fourth-consecutive-year-301699910.html
SOURCE Regeneron Pharmaceuticals, Inc.